- Home
- ISPC vs SYBX Comparison
ISPC vs SYBX Comparison
Compare ISPC & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ISPC
- SYBX
- Stock Information
- Founded
- ISPC 2009
- SYBX N/A
- Country
- ISPC United States
- SYBX United States
- Employees
- ISPC N/A
- SYBX N/A
- Industry
- ISPC Precision Instruments
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- ISPC Health Care
- SYBX Health Care
- Exchange
- ISPC Nasdaq
- SYBX Nasdaq
- Market Cap
- ISPC 13.9M
- SYBX 16.4M
- IPO Year
- ISPC 2021
- SYBX N/A
- Fundamental
- Price
- ISPC $1.55
- SYBX $1.67
- Analyst Decision
- ISPC
- SYBX
- Analyst Count
- ISPC 0
- SYBX 0
- Target Price
- ISPC N/A
- SYBX N/A
- AVG Volume (30 Days)
- ISPC 20.5M
- SYBX 21.5K
- Earning Date
- ISPC 11-06-2025
- SYBX 11-11-2025
- Dividend Yield
- ISPC N/A
- SYBX N/A
- EPS Growth
- ISPC N/A
- SYBX N/A
- EPS
- ISPC N/A
- SYBX N/A
- Revenue
- ISPC $5,908,088.00
- SYBX N/A
- Revenue This Year
- ISPC $35.93
- SYBX N/A
- Revenue Next Year
- ISPC N/A
- SYBX N/A
- P/E Ratio
- ISPC N/A
- SYBX N/A
- Revenue Growth
- ISPC N/A
- SYBX N/A
- 52 Week Low
- ISPC $0.64
- SYBX $0.90
- 52 Week High
- ISPC $8.30
- SYBX $1.96
- Technical
- Relative Strength Index (RSI)
- ISPC 56.57
- SYBX 64.76
- Support Level
- ISPC $1.47
- SYBX $1.45
- Resistance Level
- ISPC $2.58
- SYBX $1.77
- Average True Range (ATR)
- ISPC 0.47
- SYBX 0.07
- MACD
- ISPC 0.08
- SYBX 0.03
- Stochastic Oscillator
- ISPC 35.83
- SYBX 72.22
About ISPC iSpecimen Inc.
iSpecimen Inc is a technology-driven company focused on connecting life science researchers who need human biofluids, solid tissues, and hematopoietic stem and immune cells for their research, with the available biospecimens. The company generates revenue by procuring various specimens from hospitals, laboratories, and other supply sites. Geographically, it has a presence in the Americas; Europe, the Middle East, Africa, and Asia Pacific, which majority, comes from the Americas.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.